TY - JOUR
T1 - Prognostic factors for chronic active Epstein-Barr virus infection
AU - Kimura, Hiroshi
AU - Morishima, Tsuneo
AU - Kanegane, Hirokazu
AU - Ohga, Shouichi
AU - Hoshino, Yo
AU - Maeda, Akihiko
AU - Imai, Shosuke
AU - Okano, Motohiko
AU - Morio, Tomohiro
AU - Yokota, Shumpei
AU - Tsuchiya, Shigeru
AU - Yachie, Akihiro
AU - Imashuku, Shinsaku
AU - Kawa, Keisei
AU - Wakiguchi, Hiroshi
PY - 2003/2/15
Y1 - 2003/2/15
N2 - Chronic active Epstein-Barr virus infection (CAEBV) is a high-mortality and high-morbidity disease. To clarify the prognostic factors, a national survey was performed in Japan, and data for 82 patients who met the criteria for CAEBV were analyzed. Of these 82 patients, 47 were alive and 35 had already died. Multivariate analysis revealed that thromobocytopenia and age at disease onset were correlated with mortality. The probability of 5-year survival was 0.45 for older patients (onset age, ≥8 years), 0.94 for younger patients (P<.001), 0.38 for patients with thrombocytopenia (platelet count <12 × 104 platelets/μL at diagnosis), and 0.76 for patients without thrombocytopenia (P = .01). Furthermore, patients with T cell infection by EBV had shorter survival times than patients with natural killer cell infection (probability of 5-year survival, 0.59 vs. 0.87; P<.009). Patients with CAEBV with late onset of disease, thrombocytopenia, and T cell infection had significantly poorer outcomes.
AB - Chronic active Epstein-Barr virus infection (CAEBV) is a high-mortality and high-morbidity disease. To clarify the prognostic factors, a national survey was performed in Japan, and data for 82 patients who met the criteria for CAEBV were analyzed. Of these 82 patients, 47 were alive and 35 had already died. Multivariate analysis revealed that thromobocytopenia and age at disease onset were correlated with mortality. The probability of 5-year survival was 0.45 for older patients (onset age, ≥8 years), 0.94 for younger patients (P<.001), 0.38 for patients with thrombocytopenia (platelet count <12 × 104 platelets/μL at diagnosis), and 0.76 for patients without thrombocytopenia (P = .01). Furthermore, patients with T cell infection by EBV had shorter survival times than patients with natural killer cell infection (probability of 5-year survival, 0.59 vs. 0.87; P<.009). Patients with CAEBV with late onset of disease, thrombocytopenia, and T cell infection had significantly poorer outcomes.
UR - http://www.scopus.com/inward/record.url?scp=0037443050&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037443050&partnerID=8YFLogxK
U2 - 10.1086/367988
DO - 10.1086/367988
M3 - Article
C2 - 12599068
AN - SCOPUS:0037443050
SN - 0022-1899
VL - 187
SP - 527
EP - 533
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 4
ER -